트리암시놀론 시장 : 유형별, 용도별, 유통 채널별 - 세계 기회 분석과 산업 예측(2024-2033년)

Triamcinolone Market By Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,232,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,439,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

트리암시놀론 시장

트리암시놀론 시장은 2023년에 9억 달러로 평가되며, 2024-2033년 CAGR 3.8%로 성장하며, 2033년에는 13억 달러에 달할 것으로 예측됩니다.

트리암시놀론은 항염증 및 면역 억제 작용을 하는 글루코코르티코이드로 알레르기 반응, 피부 질환, 관절염, 천식과 같은 호흡기 질환 등 다양한 질환을 치료하는 데 사용됩니다. 이 화합물은 신체의 특정 부위에 작용하거나 전신적인 효과를 내기 위해 여러 형태로 존재합니다. 연고, 외용 크림, 경구용 정제, 주사제, 비강 점안제 등이 있습니다. 트리암시놀론은 히스타민과 사이토카인과 같은 염증성 물질의 방출을 억제하여 부종, 발적, 가려움증을 억제하는 데 도움이 됩니다.

만성질환의 유병률 증가, 노인 인구의 급격한 증가, 의료 인프라의 확대는 트리암시놀론 시장의 주요 촉진요인입니다. 노인들은 관절염, 천식, 피부질환과 같은 만성질환과 염증성 질환에 걸리기 쉽습니다. 강력한 코르티코스테로이드인 트리암시놀론은 효과적인 항염증 및 면역 억제 효과를 제공하여 이러한 질환의 증상을 현저하게 완화합니다. 나노 제제와 같은 첨단 약물전달 시스템을 통한 트리암시놀론의 투여는 호흡기 질환 및 만성 피부 질환의 회복 과정을 촉진하므로 치료 방법의 동향이 되고 있습니다.

그러나 특정 요인이 트리암시놀론 시장 개척을 억제하고 있습니다. 코르티코스테로이드인 트리암시놀론의 장기 사용 및 대량 투여는 체중 증가, 피부 얇아짐, 혈당 상승, 감염 위험 증가와 같은 심각한 부작용을 유발합니다. 이 때문에 트리암시놀론을 약으로 선호하지 않는 개업의와 환자가 많아 시장 성장을 억제하고 있습니다. 반대로 트리암시놀론은 다양한 건강 상태의 치료제로 검토되고 있으며, 이는 향후 적용 가능성이 높아지고 있음을 시사합니다. 최신 의료 정보 웹사이트 Medscape가 최근 발표한 기사에 따르면 트리암시놀론은 갑상선 안병증 치료에 탁월한 약물입니다. 트리암시놀론의 경피적 주사는 이 질환에서 마진반사거리1(MRD1)과 상안검후퇴(UER)를 개선하는 데 도움이 될 수 있습니다.

부문별 리뷰

트리암시놀론 시장은 유형, 용도, 유통 채널, 지역으로 분류됩니다. 유형별로 시장은 크림, 주사제, 흡입제로 나뉩니다. 용도별로는 습진, 피부염, 알레르기, 건선, 기타로 분류됩니다. 유통 채널별로는 약국, 병원 약국, 온라인 약국으로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

유형별로는 크림 부문이 2023년 시장을 장악했습니다.

용도별로는 2023년 습진 부문이 가장 큰 주주였습니다.

유통 채널별로는 2023년 약국 부문이 가장 높은 점유율을 차지했습니다.

지역별로 보면 제약 산업의 성장과 의료에 대한 투자로 인해 아시아태평양에서 시장이 빠르게 성장하고 있습니다.

이 보고서의 커스터마이징이 가능합니다(별도의 비용과 일정이 필요합니다).

• 규제 가이드라인
• 고객의 관심사에 따른 기업 개요 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확대 리스트
• 과거 시장 데이터
• 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 개요

제3장 시장 구도

• 시장의 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회

제4장 트리암시놀론 시장 : 유형별

• 시장 개요
• 크림
• 주사제
• 흡입제

제5장 트리암시놀론 시장 : 용도별

• 시장 개요
• 습진
• 피부염
• 알레르기
• 건선
• 기타

제6장 트리암시놀론 시장 : 유통 채널별

• 시장 개요
• 드러그스토어
• 병원 약국
• 온라인 약국

제7장 트리암시놀론 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 트리암시놀론 시장
  • 캐나다의 트리암시놀론 시장
  • 멕시코의 트리암시놀론 시장
• 유럽
  • 주요 시장 동향과 기회
  • 독일의 트리암시놀론 시장
  • 프랑스의 트리암시놀론 시장
  • 영국의 트리암시놀론 시장
  • 이탈리아의 트리암시놀론 시장
  • 스페인의 트리암시놀론 시장
  • 기타 유럽의 트리암시놀론 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 일본의 트리암시놀론 시장
  • 중국의 트리암시놀론 시장
  • 호주의 트리암시놀론 시장
  • 인도의 트리암시놀론 시장
  • 한국의 트리암시놀론 시장
  • 기타 아시아태평양의 트리암시놀론 시장
• 라틴아메리카·중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 트리암시놀론 시장
  • 사우디아라비아의 트리암시놀론 시장
  • 남아프리카공화국의 트리암시놀론 시장
  • 기타 라틴아메리카·중동 및 아프리카의 트리암시놀론 시장

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10 기업의 제품 지도제작
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

• Akorn Inc
• Bristol Myers Squibb Company
• Cosette Pharmaceuticals, Inc
• Glenmark Pharmaceuticals
• Lupin
• Mylan N.V.
• Novartis AG
• Sun Pharmaceutical Industries Limited
• Taro Pharmaceutical Industries
• Teva Pharmaceuticals

KSA

영문 목차

영문목차

Triamcinolone Market

The triamcinolone market was valued at $0.9 billion in 2023 and is projected to reach $1.3 billion by 2033, growing at a CAGR of 3.8% from 2024 to 2033.

Triamcinolone is a glucocorticoid with anti-inflammatory and immunosuppressive properties that is used in the treatment of various medical conditions, including allergic reactions, skin disorders, arthritis, and respiratory illnesses such as asthma. The compound exists in multiple forms to target specific areas of the body or provide systemic effects. These forms include ointments, topical creams, oral tablets, injections, and nasal sprays. Triamcinolone helps to reduce swelling, redness, and itching by inhibiting the release of inflammatory substances such as histamines & cytokines.

Increasing prevalence of chronic diseases, exponentially growing geriatric population, and expansion of healthcare infrastructure are the key drivers of the triamcinolone market. The elderly individuals are highly prone to chronic and inflammatory diseases such as arthritis, asthma, and dermatological conditions. Triamcinolone, being a potent corticosteroid, remarkably alleviates the symptoms of such diseases by providing effective anti-inflammatory and immunosuppressive advantages. The administration of triamcinolone through advanced drug delivery systems such as nano formulations is trending in the treatment procedures as it enhances the recovery process for respiratory and chronic skin conditions.

However, certain factors restrain the development of the triamcinolone market. Being a corticosteroid, prolonged usage or high doses of the compound leads to severe side-effects, including weight gain, skin thinning, increase in blood sugar levels, and high risk of infections. This deters several medical practitioners and patients from preferring triamcinolone as a medication, thereby restraining the market growth. On the contrary, triamcinolone is being explored for the treatment for different health conditions, which indicates its enhanced applicability in the future. According to a recent article published by Medscape, a website publishing latest medical information, triamcinolone is an excellent drug for the treatment of thyroid eye disease. Injection of triamcinolone percutaneously helps to improve margin reflex distance 1 (MRD1) and upper eyelid retraction (UER) in the disease.

Segment Review

The triamcinolone market is segmented into type, application, distribution channel, and region. On the basis of type, the market is divided into cream, injection, and inhalers. By application, it is classified into eczema, dermatitis, allergies, psoriasis, and others. As per distribution channel, it is categorized into drug stores, hospitals pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the cream segment dominated market in 2023.

By application, the eczema segment was the highest shareholder in 2023.

As per distribution channel, the drug store segment acquired high stakes in 2023.

Region wise, the market is rapidly expanding in Asia-Pacific owing to the growing pharmaceutical industry and investments in healthcare.

Competition Analysis

The major players operating in the global triamcinolone market include Akorn Inc, Bristol Myers Squibb Company, Cosette Pharmaceuticals, Inc, Glenmark Pharmaceuticals, Lupin, Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Limited, Taro Pharmaceutical Industries, and Teva Pharmaceuticals. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

• Cream
• Injection
• Inhalers

By Application

• Eczema
• Dermatitis
• Allergies
• Psoriasis
• Others

By Distribution Channel

• Drug Stores
• Hospitals Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Akorn Inc
• Bristol Myers Squibb Company
• Cosette Pharmaceuticals, Inc
• Glenmark Pharmaceuticals
• Lupin
• Mylan N.V.
• Novartis AG
• Sun Pharmaceutical Industries Limited
• Taro Pharmaceutical Industries
• Teva Pharmaceuticals

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: TRIAMCINOLONE MARKET, BY TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Type
• 4.2. Cream
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Injection
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country
• 4.4. Inhalers
  • 4.4.1. Key Market Trends, Growth Factors and Opportunities
  • 4.4.2. Market Size and Forecast, By Region
  • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: TRIAMCINOLONE MARKET, BY APPLICATION

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Application
• 5.2. Eczema
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Dermatitis
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country
• 5.4. Allergies
  • 5.4.1. Key Market Trends, Growth Factors and Opportunities
  • 5.4.2. Market Size and Forecast, By Region
  • 5.4.3. Market Share Analysis, By Country
• 5.5. Psoriasis
  • 5.5.1. Key Market Trends, Growth Factors and Opportunities
  • 5.5.2. Market Size and Forecast, By Region
  • 5.5.3. Market Share Analysis, By Country
• 5.6. Others
  • 5.6.1. Key Market Trends, Growth Factors and Opportunities
  • 5.6.2. Market Size and Forecast, By Region
  • 5.6.3. Market Share Analysis, By Country

CHAPTER 6: TRIAMCINOLONE MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Distribution Channel
• 6.2. Drug Stores
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Hospitals Pharmacies
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Online Pharmacies
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: TRIAMCINOLONE MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Type
  • 7.2.3. Market Size and Forecast, By Application
  • 7.2.4. Market Size and Forecast, By Distribution Channel
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Triamcinolone Market
    • 7.2.6.1. Market Size and Forecast, By Type
    • 7.2.6.2. Market Size and Forecast, By Application
    • 7.2.6.3. Market Size and Forecast, By Distribution Channel
  • 7.2.7. Canada Triamcinolone Market
    • 7.2.7.1. Market Size and Forecast, By Type
    • 7.2.7.2. Market Size and Forecast, By Application
    • 7.2.7.3. Market Size and Forecast, By Distribution Channel
  • 7.2.8. Mexico Triamcinolone Market
    • 7.2.8.1. Market Size and Forecast, By Type
    • 7.2.8.2. Market Size and Forecast, By Application
    • 7.2.8.3. Market Size and Forecast, By Distribution Channel
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Type
  • 7.3.3. Market Size and Forecast, By Application
  • 7.3.4. Market Size and Forecast, By Distribution Channel
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. Germany Triamcinolone Market
    • 7.3.6.1. Market Size and Forecast, By Type
    • 7.3.6.2. Market Size and Forecast, By Application
    • 7.3.6.3. Market Size and Forecast, By Distribution Channel
  • 7.3.7. France Triamcinolone Market
    • 7.3.7.1. Market Size and Forecast, By Type
    • 7.3.7.2. Market Size and Forecast, By Application
    • 7.3.7.3. Market Size and Forecast, By Distribution Channel
  • 7.3.8. UK Triamcinolone Market
    • 7.3.8.1. Market Size and Forecast, By Type
    • 7.3.8.2. Market Size and Forecast, By Application
    • 7.3.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3.9. Italy Triamcinolone Market
    • 7.3.9.1. Market Size and Forecast, By Type
    • 7.3.9.2. Market Size and Forecast, By Application
    • 7.3.9.3. Market Size and Forecast, By Distribution Channel
  • 7.3.10. Spain Triamcinolone Market
    • 7.3.10.1. Market Size and Forecast, By Type
    • 7.3.10.2. Market Size and Forecast, By Application
    • 7.3.10.3. Market Size and Forecast, By Distribution Channel
  • 7.3.11. Rest of Europe Triamcinolone Market
    • 7.3.11.1. Market Size and Forecast, By Type
    • 7.3.11.2. Market Size and Forecast, By Application
    • 7.3.11.3. Market Size and Forecast, By Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Type
  • 7.4.3. Market Size and Forecast, By Application
  • 7.4.4. Market Size and Forecast, By Distribution Channel
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. Japan Triamcinolone Market
    • 7.4.6.1. Market Size and Forecast, By Type
    • 7.4.6.2. Market Size and Forecast, By Application
    • 7.4.6.3. Market Size and Forecast, By Distribution Channel
  • 7.4.7. China Triamcinolone Market
    • 7.4.7.1. Market Size and Forecast, By Type
    • 7.4.7.2. Market Size and Forecast, By Application
    • 7.4.7.3. Market Size and Forecast, By Distribution Channel
  • 7.4.8. Australia Triamcinolone Market
    • 7.4.8.1. Market Size and Forecast, By Type
    • 7.4.8.2. Market Size and Forecast, By Application
    • 7.4.8.3. Market Size and Forecast, By Distribution Channel
  • 7.4.9. India Triamcinolone Market
    • 7.4.9.1. Market Size and Forecast, By Type
    • 7.4.9.2. Market Size and Forecast, By Application
    • 7.4.9.3. Market Size and Forecast, By Distribution Channel
  • 7.4.10. South Korea Triamcinolone Market
    • 7.4.10.1. Market Size and Forecast, By Type
    • 7.4.10.2. Market Size and Forecast, By Application
    • 7.4.10.3. Market Size and Forecast, By Distribution Channel
  • 7.4.11. Rest of Asia-Pacific Triamcinolone Market
    • 7.4.11.1. Market Size and Forecast, By Type
    • 7.4.11.2. Market Size and Forecast, By Application
    • 7.4.11.3. Market Size and Forecast, By Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Type
  • 7.5.3. Market Size and Forecast, By Application
  • 7.5.4. Market Size and Forecast, By Distribution Channel
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Triamcinolone Market
    • 7.5.6.1. Market Size and Forecast, By Type
    • 7.5.6.2. Market Size and Forecast, By Application
    • 7.5.6.3. Market Size and Forecast, By Distribution Channel
  • 7.5.7. Saudi Arabia Triamcinolone Market
    • 7.5.7.1. Market Size and Forecast, By Type
    • 7.5.7.2. Market Size and Forecast, By Application
    • 7.5.7.3. Market Size and Forecast, By Distribution Channel
  • 7.5.8. South Africa Triamcinolone Market
    • 7.5.8.1. Market Size and Forecast, By Type
    • 7.5.8.2. Market Size and Forecast, By Application
    • 7.5.8.3. Market Size and Forecast, By Distribution Channel
  • 7.5.9. Rest of LAMEA Triamcinolone Market
    • 7.5.9.1. Market Size and Forecast, By Type
    • 7.5.9.2. Market Size and Forecast, By Application
    • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Akorn Inc
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Bristol Myers Squibb Company
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. Cosette Pharmaceuticals, Inc
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Glenmark Pharmaceuticals
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. Lupin
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. Mylan N.V.
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. Novartis AG
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Sun Pharmaceutical Industries Limited
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Taro Pharmaceutical Industries
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Teva Pharmaceuticals
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료